Drugs / STI-3258
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05060276 | Dec 2022 → May 2024 | refractory malignant neoplasm | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STI-3258 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05060276 ↗ |
| Route | Intravenous | “STI-3258 administered intravenously” NCT05060276 ↗ |